Osimertinib (Tagrisso)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses osimertinib (Tagrisso) tablets, 40 mg and 80 mg (as osimertinib mesylate), oral. Indication: In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic non–small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 L858R substitution mutations.